Alkermes
alkermes lead candidate demonstrated potency superior to peptide in preclinical studies activation of expressing histamine neurons ala leu application of induced robust concentration dependent increases in neuronal excitability in rodent brain tissue demonstrated greater potency compared to an synthetic peptide activity ala leu alkermes data on file ala leu leu concentration | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
137 of 144
Related slides by other companies
Adagio Therapeutics
Investor Conference
March 2023
demonstrated broad in neutralizing activity against variants of concern and sub lineages tested | Adagio Therapeutics
Erasca
Investor Presentation
January 2024
is a potent and selective inhibitor of and with sub potency and most advanced pan in development | Erasca
Erasca
Investor Presentation
November 2023
is a potent and selective inhibitor of and with sub potency and most advanced pan in development | Erasca
Compass Therapeutics
IPO
November 2020
demonstrated promising activity in preclinical models of high tumor burden | Compass Therapeutics
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights